newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

  • vTv Therapeutics received $20.0 million from Newsoara in February 2026 under an amended licensing agreement granting global rights to PDE4 inhibitor HPP737
  • The company expects to complete enrollment in the CATT1 Phase 3 trial for cadisegliatin during the third quarter of 2026
  • The strengthened balance sheet provides a funding runway extending well past the anticipated CATT1 Phase 3 topline readout
  • Cash position increased to $88.9 million as of December 31, 2025, up from $36.7 million in the prior year
  • Research & Development expenses were $3.9 million for Q4 2025 & $17.9 million for the full year 2025, driven by increased clinical study spending on cadisegliatin
  • General & Administrative expenses were $4.0 million for Q4 2025 & $14.9 million for the full year 2025, attributed to higher payroll, legal, & other operating costs
  • Net loss was $7.1 million ($0.58 per share) for Q4 2025 & $27.0 million ($3.20 per share) for the full year 2025
  • The company submitted a Phase 2 clinical study protocol for cadisegliatin in type 2 diabetes to the UAE Department of Health in December 2025
  • Four new experts were appointed to the Scientific Advisory Board in October 2025 to guide the development of cadisegliatin
  • Cadisegliatin is a novel oral glucokinase activator with FDA Breakthrough Therapy designation for type 1 diabetes adjunctive therapy